-

Crocs, Inc. (CROX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Crocs, Inc. (“Crocs” or the “Company”) (NASDAQ: CROX) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CROCS, INC. (CROX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Investigation About?
In February 2022, Crocs completed its acquisition of HEYDUDE, a footwear brand focusing on casual, comfortable, and lightweight footwear.

But on April 27, 2023, Crocs revealed that HEYDUDE’s 2022 revenue growth was attributable to efforts to stock the Company’s wholesale partners with products and was not necessarily indicative of actual retail sales. On this news, Crocs’ stock price fell $23.46, or 15.9%, to close at $124.32 per share on April 27, 2023, thereby injuring investors.

Then, on June 7, 2023, the Company revealed that over half of HEYDUDE’s third quarter 2022 wholesale revenue was the result of efforts to stock HEYDUDE products with Crocs’ major retailers. On this news, Crocs’ stock price fell $4.52, or 3.7%, to close at $116.57 per share on June 8, 2023.

Shortly after, on July 27, 2023, Crocs admitted that its deliberate overstocking accounted for approximately $220 million of HEYDUDE’s $896 million in revenue for the period directly following the closing of the acquisition. The Company also announced that it was reducing HEYDUDE’s revenue growth guidance for the remainder of 2023. On this news, Crocs’ stock price fell $17.50, or 14.6%, to close at $102.30 per share on July 27, 2023.

Then, on August 16, 2023, Williams Trading LLC significantly decreased its price target on Crocs, citing elevated HEYDUDE inventory levels. On this news, Crocs’ stock price fell $3.79, or 3.9%, to close at $94.01 per share on August 16, 2023.

Further, on November 2, 2023, Crocs released its third quarter 2023 financial results, revealing that HEYDUDE’s wholesale revenue had declined significantly “following prior year pipeline fill.” Crocs slashed its 2023 HEYDUDE revenue growth guidance from 14%-18% to only 4%-6%. On this new, Crocs’ stock price fell $4.62, or 5.3%, to close at $82.79 per share on November 2, 2023.

Finally, on October 29, 2024, the Company hosted an earnings call, during which Chief Executive Officer Andrew Rees revealed that HEYDUDE revenue had fallen below expectations once again, and was struggling due to “excess inventories in the market.” Moreover, Andrew Reese admitted that “in retrospect, we absolutely shipped too much product.”

On this news, Crocs’ stock price fell $26.47, or 19.2%, to close at $111.58 per share on October 29, 2024.

Contact Us To Participate or Learn More:
If you purchased Crocs securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NASDAQ:CROX

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 89.77% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation comes after a August 10, 2026 disclosure concerning Tenax Therapeutics, Inc....

Did You Lose Money on Everest Group, Ltd. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 11.4% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Everest Group, Ltd. ("Everest" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Everest Group, Ltd. (NYSE: EG) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 27, 2025 disclosure concerning Everest Group, Ltd.Investors with los...

Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may have violated the federal securities laws. The investigation comes after an October 22, 2026 disclosure concerning Merck & Co., Inc. Investors...
Back to Newsroom